CA2362204A1 - Immunogenic complexes and methods relating thereto - Google Patents
Immunogenic complexes and methods relating thereto Download PDFInfo
- Publication number
- CA2362204A1 CA2362204A1 CA002362204A CA2362204A CA2362204A1 CA 2362204 A1 CA2362204 A1 CA 2362204A1 CA 002362204 A CA002362204 A CA 002362204A CA 2362204 A CA2362204 A CA 2362204A CA 2362204 A1 CA2362204 A1 CA 2362204A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine composition
- adjuvant
- immunogenic complex
- composition according
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Abstract
The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen. The complexes of the present invention are useful, inter alia, as therapeutic and/or prophylactic agents for facilitating the induction of a cytotoxic T- lymphocyte response to an antigen.
Claims (51)
1. An immunogenic complex comprising a charged organic carrier and a charged antigen, which organic carrier and antigen are electrostatically associated.
2. The immunogenic complex according to claim 1 wherein said carrier is negatively charged and said antigen is positively charged.
3. The immunogenic complex according to claim 2 wherein said antigen is a protein or derivative or equivalent thereof.
4. The immunogenic complex according to claim 2 wherein said carrier is an adjuvant or derivative or equivalent thereof.
5. The immunogenic complex according to claim 2 wherein said antigen is a protein or derivative or equivalent thereof and said carrier is an adjuvant or derivative or equivalent thereof.
6. The immunogenic complex according to claim 5 wherein said negatively charged adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge.
7. The immunogenic complex according to claim 5 wherein said positively charged protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
8. The immunogenic complex according to claim 5 wherein said negatively charged adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge and said positively charged protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
9. The immunogenic complex according to any one of claims 5-8 wherein said adjuvant comprises a saponin.
10. The immunogenic complex according to any one of claims 5-8 wherein said adjuvant is a saponin complex.
11. The immunogenic complex according to claim 10 wherein said saponin complex is ISCOMATRIXT.TM..
12. The immunogenic complex according to any one of claims 5-8 wherein said adjuvant comprises a phospholipid.
13. The immunogenic complex according to claim 12 wherein said phospholipid is a phosphoglyceride.
14. The immunogenic complex according to claim 13 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.
15. The immunogenic complex according to claim 12 wherein said phospholipid is lipid A.
16. The immunogenic complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A such as OM174 and monophosphoryl lipid A.
17. The immunogenic complex according to any one of claims 1-16 wherein said complex induces a cytotoxic T-lymphocyte response.
18. A vaccine composition comprising as the active component a charged organic carrier and a charged antigen, which carrier and antigen are electrostatically associated, together with one or more pharmaceutically acceptable carriers and/or diluents.
19. The vaccine composition according to claim 18 wherein said carrier is negatively charged and said antigen is positively charged.
20. The vaccine composition according to claim 19 wherein said antigen is a protein or derivative or equivalent thereof.
21. The vaccine composition according to claim 19 wherein said carrier is an adjuvant or derivative or equivalent thereof.
22. The vaccine composition according to claim 19 wherein said antigen is a protein or derivative or equivalent thereof and said carrier is an adjuvant or derivative or equivalent thereof.
23. The vaccine composition according to claim 22 wherein said negatively charged adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge.
24. The vaccine composition according to claim 22 wherein said positively charged protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
25. The vaccine composition according to claim 22 wherein said negatively charged adjuvant is a naturally negatively charged adjuvant which has been modified to increase the degree of its negative charge and said positively charged protein is a naturally positively charged protein which has been modified to increase the degree of its positive charge.
26. The vaccine composition according to any one of claims 22-25 wherein said adjuvant comprises a saponin.
27. The immunogenic complex according to any one of claims 22-25 wherein said adjuvant is a saponin complex.
28. The vaccine composition according to claim 27 wherein said saponin complex is ISCOMATRIX.TM..
29. The vaccine composition according to any one of claims 22-25 wherein said adjuvant comprises a phospholipid.
30. The vaccine composition according to claim 29 wherein said phospholipid is a phosphoglyceride.
31. The vaccine composition according to claim 30 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.
32. The vaccine composition according to claim 29 wherein said phospholipid is lipid A.
33. The vaccine composition according to claim 32 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A such as OM174 and monophosphoryl lipid A.
34. The vaccine composition according to any one of claims 18-33 wherein said composition induces a cytotoxic T-lymphocyte response.
35. A method of eliciting, inducing or otherwise facilitating, in a mammal, an immune response to an antigen said method comprising administering to said mammal an effective amount of an immunogenic complex according to any one of claims 1-17.
36. A method of eliciting, inducing or otherwise facilitating, in a mammal, an immune response to an antigen said method comprising administering to said mammal an effective amount of a vaccine composition according to any one of claims 18-34.
37. The method according to claim 17 or 36 wherein said immune response comprises a cytotoxic T-lymphocyte response.
38. A method of treating a disease condition in a mammal said method comprising administering to said mammal an effective amount of an immunogenic complex according to any one of claims 1-17 wherein administering said complex elicits, induces or otherwise facilitates an immune response which inhibits, halts, delays or prevents the onset or progression of said disease condition.
39. A method of treating a disease condition in a mammal said method comprising administering to said mammal an effective amount of a vaccine composition according to any one of claims 18-34 wherein administering said composition elicits, induces or otherwise facilitates an immune response which inhibits, halts, delays or prevents the onset or progression of the disease condition.
40. The method according to claim 38 or 39 wherein said immune response comprises a cytotoxic T-lymphocyte response.
41. The method according to any one of claims 38-41 wherein said treatment is therapeutic or prophylactic.
42. The method according to any one of claims 38-41 wherein said disease condition results from a microbial infection or a cancer.
43. The method according to claim 43 wherein said microbial infection is HIV, Hepatitis B, Hepatitis C, tuberculosis or a parasitic condition and said cancer is melanoma, prostate cancer or breast cancer.
44. Use of an immunogenic complex according to any one of claims 1-17 in the manufacture of a medicament for inhibiting, halting, delaying or preventing the onset or progression of a disease condition.
45. Use of a vaccine composition according to any one of claims 18-34 in the manufacture of a medicament for inhibiting, halting, delaying or preventing the onset or progression of a disease condition.
46. Use according to claim 44 or 45 wherein said disease condition results from a microbial infection or a cancer.
47. Use according to claim 46 wherein said microbial infection is HIV, Hepatitis B, Hepatitis C, tuberculosis or a parasitic infection and said cancer is melanoma, prostate cancer or breast cancer.
48. An agent for use in inhibiting, halting, delaying or preventing the onset or progression of a disease condition wherein said agent comprises an immunogenic complex according to any one of claims 1-17.
49. An agent for use in inhibiting, halting, delaying or preventing the onset or progression of a disease condition wherein said agent comprises a vaccine composition according to any one of claims 18-34.
50. An agent according to claim 48 or 49 wherein said disease condition results from a microbial infection or a cancer.
51. An agent according to claim 50 wherein said microbial infection is HIV, Hepatitis B, Hepatitis C, tuberculosis or a parasitic infection and said cancer is melanoma, prostate cancer or breast cancer.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP8735 | 1999-02-17 | ||
AUPP8735A AUPP873599A0 (en) | 1999-02-17 | 1999-02-17 | Immunogenic compositions and methods relating thereto |
AUPQ1861 | 1999-07-27 | ||
AUPQ1861A AUPQ186199A0 (en) | 1999-07-27 | 1999-07-27 | Immunogenic complexes and methods relating thereto-ii |
PCT/AU2000/000110 WO2000048630A1 (en) | 1999-02-17 | 2000-02-17 | Immunogenic complexes and methods relating thereto |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2362204A1 true CA2362204A1 (en) | 2000-08-24 |
CA2362204C CA2362204C (en) | 2011-11-08 |
Family
ID=25645995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2362204A Expired - Lifetime CA2362204C (en) | 1999-02-17 | 2000-02-17 | Immunogenic complexes and methods relating thereto |
Country Status (12)
Country | Link |
---|---|
US (2) | US7776343B1 (en) |
EP (2) | EP2204186B1 (en) |
JP (1) | JP5084984B2 (en) |
AT (1) | ATE464907T1 (en) |
AU (1) | AU783344B2 (en) |
CA (1) | CA2362204C (en) |
DE (1) | DE60044236D1 (en) |
DK (1) | DK2204186T3 (en) |
ES (1) | ES2572834T3 (en) |
HK (1) | HK1039895B (en) |
NZ (1) | NZ513935A (en) |
WO (1) | WO2000048630A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2204186B1 (en) * | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
WO2001037869A1 (en) * | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
GB0008877D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
GB0008879D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
EP1467755A1 (en) * | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
EP2484374A1 (en) * | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
MX2007009598A (en) * | 2005-02-08 | 2008-03-10 | Queensland Inst Med Res | Immunogenic molecules. |
CN101820904A (en) * | 2007-10-12 | 2010-09-01 | Csl有限公司 | Method of eliciting an immune response against pandemic influenza virus |
SG10201400388QA (en) | 2008-12-09 | 2014-05-29 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
SG177637A1 (en) | 2009-07-30 | 2012-03-29 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
SG10201401516XA (en) | 2009-09-03 | 2014-10-30 | Pfizer Vaccines Llc | Pcsk9 vaccine |
NZ629256A (en) | 2009-12-22 | 2016-02-26 | Celldex Therapeutics Inc | Vaccine compositions |
EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US8895017B2 (en) | 2010-06-07 | 2014-11-25 | Pfizer Inc. | HER-2 peptides and vaccines |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
CA2845884A1 (en) | 2011-08-22 | 2013-02-28 | Cangene Corporation | Clostridium difficile antibodies |
KR101951365B1 (en) | 2012-02-08 | 2019-04-26 | 삼성디스플레이 주식회사 | Liquid crystal display device |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659908A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
JP6274668B2 (en) * | 2012-10-22 | 2018-02-07 | 国立大学法人 奈良先端科学技術大学院大学 | Adjuvant and vaccine containing the same |
PE20212335A1 (en) | 2014-01-21 | 2021-12-16 | Pfizer | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
EP3107567A4 (en) | 2014-02-19 | 2017-10-25 | Cangene Corporation | Methods of modulating an immune response |
WO2015157629A2 (en) | 2014-04-10 | 2015-10-15 | Obi Pharma Inc. | Antibodies, pharmaceutical compositions and uses thereof |
PT3244917T (en) | 2015-01-15 | 2023-05-31 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
WO2016193405A1 (en) | 2015-06-03 | 2016-12-08 | Affiris Ag | Il-23-p19 vaccines |
EP3319988A1 (en) | 2015-07-07 | 2018-05-16 | Affiris AG | Vaccines for the treatment and prevention of ige mediated diseases |
KR102225282B1 (en) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | Immunogenic composition comprising conjugated capsular saccharide antigen, kit comprising same, and use thereof |
IL257800B2 (en) | 2015-09-03 | 2023-11-01 | Novavax Inc | Vaccine compositions having improved stability and immunogenicity |
CN116063481A (en) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | Humanized anti-CD 40 antibodies and uses thereof |
WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
KR20180121786A (en) | 2016-03-29 | 2018-11-08 | 오비아이 파머 인코퍼레이티드 | Antibodies, pharmaceutical compositions and methods |
KR20230110820A (en) | 2016-04-22 | 2023-07-25 | 오비아이 파머 인코퍼레이티드 | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
CN110072545A (en) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | Immunogenicity/therapeutic glycan pool object and application thereof |
KR102528998B1 (en) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | Human Antibodies, Pharmaceutical Compositions and Methods |
JP2019535731A (en) | 2016-11-21 | 2019-12-12 | オービーアイ ファーマ,インコーポレイテッド | Conjugated biological molecules, pharmaceutical compositions and methods |
WO2018134693A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
JP7317796B2 (en) | 2017-07-24 | 2023-07-31 | ノババックス,インコーポレイテッド | Methods and compositions for treating respiratory diseases |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
EP4051696A1 (en) | 2019-11-01 | 2022-09-07 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
MX2022010350A (en) | 2020-02-23 | 2022-09-19 | Pfizer | Compositions and methods thereof. |
JP2023546615A (en) | 2020-10-27 | 2023-11-06 | ファイザー・インク | E. coli composition and method thereof |
WO2022097010A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
US11786592B2 (en) * | 2021-05-19 | 2023-10-17 | The University Of Hong Kong | Compositions of cardiolipin adjuvants and methods of use thereof |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (en) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD. |
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
US5897873A (en) * | 1984-04-12 | 1999-04-27 | The Liposome Company, Inc. | Affinity associated vaccine |
SE8405493D0 (en) * | 1984-11-01 | 1984-11-01 | Bror Morein | IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS |
DE3775783D1 (en) | 1986-01-14 | 1992-02-20 | Nederlanden Staat | METHOD FOR PRODUCING IMMUNOLOGICAL COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM. |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5583112A (en) | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
EP0380607B1 (en) | 1988-05-17 | 1994-12-14 | FERRONE, Soldano | Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen |
WO1990001947A1 (en) * | 1988-08-25 | 1990-03-08 | The Liposome Company, Inc. | Affinity associated vaccine |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5190870A (en) * | 1989-05-16 | 1993-03-02 | Amoco Corporation | Method for oxidizing hydrocarbons with a hydroxylase from a methane monooxygenase |
US5178880A (en) * | 1989-07-25 | 1993-01-12 | Norwich Eaton Pharmaceuticals, Inc. | Liquid suspensions of nitrofurantoin |
US5178860A (en) | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
US4981684A (en) | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5273965A (en) | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
US5650398A (en) | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
US5443534A (en) | 1992-07-21 | 1995-08-22 | Vlt Corporation | Providing electronic components for circuity assembly |
CA2147480A1 (en) | 1992-10-30 | 1994-05-11 | Kristian Dalsgard | Cultured cells of quillaja sp. |
ES2231773T3 (en) | 1993-05-05 | 2005-05-16 | Common Services Agency | VIRUSES OF HEPATITIS C TYPE 4, 5 AND 6. |
DE4321946A1 (en) | 1993-07-01 | 1995-01-12 | Hoechst Ag | Methylphosphonic acid esters, process for their preparation and their use |
US5859231A (en) | 1993-09-03 | 1999-01-12 | Duke University | Synthesis of oligonucleotides with boranophosphonate linkages |
AU1077795A (en) | 1993-09-30 | 1995-04-18 | Seed Capital Investments (Sci) B.V. | Compounds with adjuvant activity |
US6005099A (en) | 1993-11-17 | 1999-12-21 | Laboratoires Om S.A. | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030050263A1 (en) | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5612030A (en) | 1995-01-17 | 1997-03-18 | University Of Kentucky Research Foundation | Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
UA56132C2 (en) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US6190870B1 (en) | 1995-08-28 | 2001-02-20 | Amcell Corporation | Efficient enrichment and detection of disseminated tumor cells |
US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US5795582A (en) * | 1996-02-07 | 1998-08-18 | Novavax, Inc. | Adjuvant properties of poly (amidoamine) dendrimers |
SE9600648D0 (en) | 1996-02-21 | 1996-02-21 | Bror Morein | Receptor binding unit |
CO4600681A1 (en) * | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | PHARMACEUTICAL COMPOSITION FOR IMMUNITY MODULATION |
US6251603B1 (en) | 1996-10-03 | 2001-06-26 | Ludwig Institute For Cancer Research | Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample |
ATE292980T1 (en) | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
SE9604296D0 (en) * | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
WO1998051327A1 (en) * | 1997-05-16 | 1998-11-19 | Toray Industries, Inc. | Therapeutic agent, treatment method, prophylactic agent, and prophylactic method for canine and feline immunological diseases |
EP0996451B1 (en) | 1997-05-20 | 2005-01-05 | Galenica Pharmaceuticals, Inc. | Triterpene saponin analogs having adjuvant and immunostimulatory activity |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
ATE408422T1 (en) | 1997-07-03 | 2008-10-15 | Donald E Macfarlane | METHOD FOR INHIBITING IMMUNO-STIMULATORY RESPONSE ASSOCIATED WITH DNA |
US6355244B1 (en) | 1997-11-17 | 2002-03-12 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of psoriasis |
US20050031638A1 (en) | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
ES2284247T3 (en) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS. |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
IL139646A0 (en) | 1998-05-14 | 2002-02-10 | Coley Pharm Group Inc | Methods for regulating hematopoiesis using cpg-oligonucleotides |
JP4860039B2 (en) | 1998-05-19 | 2012-01-25 | リサーチ ディベロップメント ファンデーション | Triterpene compositions and methods of use thereof |
EP1733735B1 (en) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6339038B1 (en) * | 1998-06-16 | 2002-01-15 | Tanaka Kikinzoku Kogyo K. K. | Catalyst for a fuel cell containing polymer solid electrolyte and method for producing catalyst thereof |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
JP4620251B2 (en) | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Composition of CPG and saponin adjuvant and method thereof |
CA2341338A1 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
FR2783170B1 (en) | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | IMMUNOSTIMULATING EMULSION |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2204186B1 (en) * | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
WO2000054803A2 (en) | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
CA2372960C (en) | 1999-05-06 | 2006-03-28 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2000075304A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
CA2412345A1 (en) | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
US7496632B2 (en) * | 1999-06-28 | 2009-02-24 | Lockheed Martin Corporation | Method and system for distributing a public information release authorization (PIRA) form over an intranet |
US6299622B1 (en) * | 1999-08-19 | 2001-10-09 | Fox Hollow Technologies, Inc. | Atherectomy catheter with aligned imager |
WO2001015727A2 (en) | 1999-09-02 | 2001-03-08 | Antigenics Inc. | Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof |
AP1775A (en) | 1999-09-25 | 2007-08-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
MXPA02003059A (en) | 1999-09-27 | 2002-09-30 | Univ Iowa Res Found | Methods related to immunostimulatory nucleic acid induced interferon. |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
WO2001037869A1 (en) * | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
JP4659937B2 (en) | 1999-11-19 | 2011-03-30 | ナノキャリア株式会社 | Core-shell structure polyion complex micelle |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
CA2397374A1 (en) | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
AU3108001A (en) | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
FR2805265B1 (en) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | IMMUNOSTIMULATING OLIGONUCLEOTIDES |
US20020156033A1 (en) | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US6339630B1 (en) * | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
PT2275449T (en) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20020091097A1 (en) | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
WO2002022809A2 (en) | 2000-09-15 | 2002-03-21 | Coley Pharmaceutical Gmbh | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
FR2814958B1 (en) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | VACCINE COMPOSITION |
AU4433702A (en) | 2000-10-18 | 2002-04-29 | Smithkline Beecham Biolog | Vaccines |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP1985702A3 (en) | 2000-12-08 | 2010-08-18 | Coley Pharmaceutical GmbH | CPG-like nucleic acids and methods of use thereof |
US20030050268A1 (en) | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7581103B2 (en) * | 2001-06-13 | 2009-08-25 | Intertrust Technologies Corporation | Software self-checking systems and methods |
AU2002318944A1 (en) | 2001-08-01 | 2003-02-17 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
SG177000A1 (en) | 2001-08-17 | 2012-01-30 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
FR2830940B1 (en) | 2001-10-17 | 2007-06-15 | Commissariat Energie Atomique | METHOD FOR SELECTING HLA-DP4 LIGANDS AND ITS APPLICATIONS |
US6639814B2 (en) | 2001-12-03 | 2003-10-28 | Delta Electronics, Inc. | Constant voltage reset circuit for forward converter |
EP1467755A1 (en) | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
EP3006043B1 (en) | 2002-04-04 | 2019-05-29 | Zoetis Belgium S.A. | Immunostimulatory g,u-containing oligoribonucleotides |
US20040009949A1 (en) | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
WO2004007743A2 (en) | 2002-07-17 | 2004-01-22 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
WO2004039950A2 (en) | 2002-10-25 | 2004-05-13 | Chiron Corporation | Activation of hcv-specific cells |
ZA200503511B (en) | 2002-10-29 | 2006-10-25 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
JP3931139B2 (en) * | 2002-12-27 | 2007-06-13 | 興和株式会社 | Ophthalmic imaging equipment |
AU2004226605A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
JP2007528563A (en) * | 2003-05-09 | 2007-10-11 | エルジー エレクトロニクス インコーポレーテッド | Recording medium having data structure for managing at least data area of recording medium, and recording / reproducing method and apparatus |
DE602004028468D1 (en) | 2003-06-17 | 2010-09-16 | Mannkind Corp | ATTACHMENT OF IMMUNE RESPONSES TO MHC CLASS I RESTRICTED EPITOPES, FOR PROPHYLACTIC OR THERAPEUTIC PURPOSES |
BRPI0411514A (en) | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | small molecule toll-like receptor antagonists |
DE602004030343D1 (en) | 2003-07-11 | 2011-01-13 | Intercell Ag | HCV VACCINE |
US20050013812A1 (en) | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20050017047A1 (en) * | 2003-07-22 | 2005-01-27 | Bentley Fastening Tools Co., Ltd. | Nail-guiding grooves of the nail cartridge of a nailing gun |
BRPI0413334A (en) | 2003-09-05 | 2006-10-10 | Sanofi Pasteur Ltd | multigene vectors for melanoma |
AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
CN101454451A (en) | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
EP1720568A2 (en) | 2004-02-19 | 2006-11-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral rna oligonucleotides |
US20050222072A1 (en) | 2004-02-20 | 2005-10-06 | Hybridon, Inc. | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides |
AU2005243250A1 (en) | 2004-04-02 | 2005-11-24 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids for inducing IL-10 responses |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
US20070190072A1 (en) | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
JP2008531018A (en) | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Immunostimulatory oligonucleotide |
JP2008535859A (en) | 2005-04-08 | 2008-09-04 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Methods for treating asthma exacerbated by infection |
WO2006116458A2 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
-
2000
- 2000-02-17 EP EP10003539.3A patent/EP2204186B1/en not_active Expired - Lifetime
- 2000-02-17 DK DK10003539.3T patent/DK2204186T3/en active
- 2000-02-17 EP EP00904734A patent/EP1150710B1/en not_active Expired - Lifetime
- 2000-02-17 JP JP2000599420A patent/JP5084984B2/en not_active Expired - Fee Related
- 2000-02-17 ES ES10003539.3T patent/ES2572834T3/en not_active Expired - Lifetime
- 2000-02-17 WO PCT/AU2000/000110 patent/WO2000048630A1/en active IP Right Grant
- 2000-02-17 AT AT00904734T patent/ATE464907T1/en active
- 2000-02-17 DE DE60044236T patent/DE60044236D1/en not_active Expired - Lifetime
- 2000-02-17 NZ NZ513935A patent/NZ513935A/en not_active IP Right Cessation
- 2000-02-17 US US09/506,011 patent/US7776343B1/en not_active Expired - Fee Related
- 2000-02-17 CA CA2362204A patent/CA2362204C/en not_active Expired - Lifetime
- 2000-02-17 AU AU26515/00A patent/AU783344B2/en not_active Expired
-
2002
- 2002-02-18 HK HK02101178.0A patent/HK1039895B/en unknown
-
2009
- 2009-07-01 US US12/458,116 patent/US8173141B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ513935A (en) | 2004-02-27 |
EP2204186B1 (en) | 2016-04-06 |
EP2204186A1 (en) | 2010-07-07 |
DE60044236D1 (en) | 2010-06-02 |
HK1039895A1 (en) | 2002-05-17 |
AU2651500A (en) | 2000-09-04 |
ATE464907T1 (en) | 2010-05-15 |
JP5084984B2 (en) | 2012-11-28 |
EP1150710A1 (en) | 2001-11-07 |
US20100010193A1 (en) | 2010-01-14 |
US7776343B1 (en) | 2010-08-17 |
JP2002537271A (en) | 2002-11-05 |
EP1150710A4 (en) | 2003-09-03 |
CA2362204C (en) | 2011-11-08 |
DK2204186T3 (en) | 2016-07-18 |
EP1150710B1 (en) | 2010-04-21 |
HK1039895B (en) | 2010-12-03 |
WO2000048630A1 (en) | 2000-08-24 |
AU783344B2 (en) | 2005-10-20 |
US8173141B2 (en) | 2012-05-08 |
ES2572834T3 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2362204A1 (en) | Immunogenic complexes and methods relating thereto | |
Zamani et al. | MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer | |
Weiss | MER and other mycobacterial fractions in the immunotherapy of cancer | |
AU2006312013B2 (en) | Concurrent chemotherapy and immunotherapy | |
Tomai et al. | TLR7/8 agonists as vaccine adjuvants | |
WO2002034205A3 (en) | Using heat shock proteins to increase immune response | |
JP2009298806A (en) | Pharmaceutical composition comprising polynucleotide and optionally antigen especially for vaccination | |
AU7856700A (en) | Composition and method of cancer antigen immunotherapy | |
Warger et al. | Initiation of adaptive immune responses by transcutaneous immunization | |
Johnston et al. | Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine | |
Spitler | Cancer vaccines: the interferon analogy | |
EP1660040B1 (en) | In vivo targeting of dendritic cells | |
EP0719150A4 (en) | Cellular vaccine and methods of use for the treatment of solid tumor malignancies | |
MXPA03003638A (en) | Vaccine immunotherapy for immune suppressed patients. | |
CA2354046A1 (en) | New cancer treatments | |
Zitvogel et al. | Dendritic cells or their exosomes are effective biotherapies of cancer | |
AU2003212170A1 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
EP0422164B1 (en) | Large multivalent immunogen | |
JP2002226397A (en) | Acellular vaccine | |
KR102047323B1 (en) | Autologous cancer cell vaccine | |
CA2354045A1 (en) | New cancer treatments | |
US20060228342A1 (en) | Method for generating antigen-presenting cells | |
Durrant et al. | Cancer vaccines entering Phase III clinical trials | |
WO2002053176A3 (en) | An autologous anti-cancer vaccine | |
Hassan et al. | Naloxone can improve the anti-tumor immunity by reducing the CD4+ CD25+ Foxp3+ regulatory T cells in BALB/c mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200217 |